Personalized mRNA Vaccine Shows Durable Immune Responses in Triple-Negative Breast Cancer Trial
Key Insights
A first-in-human trial of BioNTech's personalized mRNA neoantigen vaccine in 14 triple-negative breast cancer (search) patients demonstrated that all participants developed T-cell responses against multiple tumor-specific mutations.
After a median follow-up of 62 months, 11 of 14 patients remained relapse-free, with vaccine-induced CD8 (search)+ T cells persisting for years without booster vaccinations.
The study revealed important immune escape mechanisms in the three patients who experienced recurrence, including MHC class I (search) downregulation and genetically distinct tumor origins.
A pioneering personalized mRNA vaccine developed by BioNTech has demonstrated remarkable immune durability in patients with triple-negative breast cancer (search) (TNBC (search)), with most participants remaining disease-free for up to six years in a first-in-human trial published in Nature.
The Phase I study enrolled 14 patients with early-stage TNBC (search) who had completed standard treatment within one year. Each received a personalized vaccine encoding up to 20 tumor-specific neoantigens identified through next-generation sequencing of their resected tumor tissue.
Robust and Sustained Immune Activation
All 14 evaluable patients generated vaccine-induced T-cell responses against at least one personalized neoantigen, with nine patients developing responses targeting five or more mutations. High-magnitude immune responses were detected in 86% of patients via interferon gamma ELISpot assays, with several individuals demonstrating 2,000 to 4,000 interferon gamma-producing cells per million peripheral blood mononuclear cells.
The vaccine's design, utilizing RNA-lipoplex molecules formulated in liposomal nanoparticles for intravenous administration, successfully stimulated both CD4 (search)+ helper T cells and CD8 (search)+ cytotoxic T lymphocytes. Among tested mutations, 64% elicited responses mediated exclusively by CD4+ T cells, 20% by CD8+ T cells, and 16% by both cell types.
Remarkably, neoantigen-specific CD8 (search)+ T cells constituted up to 17.5% of circulating cells during vaccination and persisted for years. In one case, 10.3% of circulating CD8+ T cells recognized a single mutation at treatment completion, with more than 3% remaining detectable two years later without booster vaccination.
Long-Term Clinical Outcomes
After a median follow-up of 62 months, 10 of 14 patients remained relapse-free, with one additional patient remaining disease-free until death from unrelated causes. This outcome is particularly noteworthy given TNBC (search)'s aggressive nature and high recurrence risk within the first three years after diagnosis.
The vaccine induced both late-stage cytotoxic effector memory cells capable of rapid tumor killing and stem cell-like memory T cells expressing markers associated with long-term immune regeneration and potential responsiveness to immune checkpoint blockade.
Insights from Treatment Failures
The three recurrence cases provided valuable mechanistic insights. One patient with the weakest vaccine-induced immune response subsequently achieved complete remission lasting 15 months following anti-PD-1 therapy (search) combined with sequential chemotherapy, suggesting potential synergy with checkpoint inhibitors.
Another case demonstrated tumor immune escape through downregulation and loss of MHC class I (search) expression, impairing antigen presentation while not fully neutralizing circulating T-cell responses. The third recurrence arose from a genetically distinct contralateral tumor not represented in the original vaccine design.
Clinical Implications and Future Directions
According to Marcus Schmidt from the University Medical Centre Mainz (search), who led the study in collaboration with BioNTech, the findings position individualized mRNA neoantigen vaccination as a promising adjuvant strategy in high-risk TNBC (search). The approach addresses a critical unmet need, as TNBC lacks expression of estrogen, progesterone, and HER2 (search) receptors, limiting eligibility for targeted therapies.
A BioNTech spokesperson indicated that similar immune signals have been observed in other indications, referencing additional publications on neoantigen RNA vaccines in pancreatic and other advanced solid tumors. Several ongoing Phase II trials are evaluating this approach across different indications to establish definitive proof of concept against standard care.
While the small sample size and absence of a randomized control group limit definitive conclusions regarding clinical efficacy, the study demonstrates that personalized mRNA vaccines are feasible, safe, and highly immunogenic in early-stage TNBC (search) patients. The generation of durable, functional immunity supports the biological plausibility of sustained immune surveillance in this aggressive cancer subtype.